A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
A phase 3 trial of Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
Overview
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia is a phase 3 interventional study registered as NCT07277231 by BeOne Medicines, with 500 participants planned, started 2026-01-22 and due to reach its primary completion in 2031-02. Interventions recorded: Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialStudy of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Acalabrutinib, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Shares Acalabrutinib, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Shares Acalabrutinib, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.